Metsera
Biotechnology company developing next-generation obesity and metabolic disease therapies, including novel GLP-1 agonists and other innovative approaches to weight management.
Website
https://www.metsera.comLocation
New York, New York, USA
Founded
2022
Investors
3
Categories
therapeutics, biotech, pharma, obesity, metabolic-disease, cardiovascular, glp-1
Notes
Metsera is a biotechnology company focused on developing innovative therapies for obesity and metabolic diseases. The company is part of the rapidly growing market for weight loss therapeutics, developing next-generation treatments that aim to improve upon current GLP-1 receptor agonists with better efficacy, tolerability, and convenience.
With significant venture backing including a $290 million Series D round in April 2024, Metsera is well-positioned to advance its pipeline of metabolic disease therapeutics through clinical development.
Team
- John Hotta - Chief Executive Officer
- LinkedIn: linkedin.com/in/johnhotta
Additional Research Findings
- Founded in 2022
- Headquarters in New York City
- Raised $290 million in Series D funding (April 2024)
- Led by ARCH Venture Partners
- Focus on obesity and metabolic disease therapeutics
- Developing next-generation weight loss treatments
- Part of rapidly growing GLP-1 and obesity market
- Multiple programs in clinical development
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| ARCH Venture Partners | Chicago, USA | biotech-focused | seedseries-a+3 | 6 |
| SoftBank Vision Fund | Tokyo, Japan & London, UK | generalist | series-bseries-c+1 | 2 |
| Mubadala Capital | Abu Dhabi, UAE | pe | series-bseries-c+1 | 1 |